Johnson & Johnson has bought the controlling shares of Switzerland-based Actelion, with an immediate finalization of the transaction.
As part of the deal, Johnson & Johnson will have access to Actelion’s newly developed biopharmaceutical company R&D NewCo. Johnson & Johnson will hold 16 percent of all shares in R&D NewCo., and any products they develop.
“We believe this transaction offers compelling value to both Johnson & Johnson and Actelion shareholders,”
Johnson & Johnson Chairman and CEO
Alex Gorsky said. “Actelion has built and attractive, growing business with world-class commercial and clinical development capabilities. Adding Actelion’s portfolio to our already strong Janssen Pharmaceuticals business is a unique opportunity for us to expand our portfolio with leading differentiated in-market medicines and promising late-stage products.”
Johnson & Johnson purchases Swiss biopharm company
Alerts Sign-up